文献速递哮喘

全球哮喘倡议2021策略报告:执行摘要与关键变更依据

Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.
PubMed 文献 · Respirology · 2022-01-01

本文总结GINA 2021关键推荐及近期变更证据。GINA建议成人及青少年哮喘不应单用短效β2受体激动剂(SABA),因SABA单药治疗和过度使用存在风险,且有吸入糖皮质激素(ICS)获益证据。大型试验显示按需ICS-福莫特罗联合治疗较单用SABA在轻度哮喘中减少严重急性发作≥60%,且与每日ICS加按需SABA的急性发作、症状、肺功能和炎症结局相似。

要点

  • 成人及青少年哮喘不应单用SABA治疗,因存在风险且ICS有获益证据。
  • 轻度哮喘按需ICS-福莫特罗较单用SABA减少严重急性发作≥60%。
  • GINA 2021成人青少年治疗图分两轨,首选轨以低剂量ICS-福莫特罗为缓解剂。

核心结论

  • GINA建议成人及青少年哮喘不应单用SABA治疗,因SABA单药治疗和过度使用存在风险且有ICS获益证据。
  • 大型试验显示按需ICS-福莫特罗联合治疗较单用SABA在轻度哮喘中减少严重急性发作≥60%。
  • 按需ICS-福莫特罗与每日ICS加按需SABA的急性发作、症状、肺功能和炎症结局相似。

研究设计与样本

  • GINA策略报告为每年更新的循证哮喘管理与预防策略,可适应本地情况如药物可及性。
  • 本文总结GINA 2021关键推荐及近期变更的证据依据。

主要发现

  • 大型试验显示按需ICS-福莫特罗联合治疗较单用SABA在轻度哮喘中减少严重急性发作≥60%。
  • 按需ICS-福莫特罗与每日ICS加按需SABA的急性发作、症状、肺功能和炎症结局相似。
  • GINA 2021将成人及青少年治疗图分为两轨,首选轨以低剂量ICS-福莫特罗为缓解剂。

关键数值与推荐

  • 首选轨(Track 1):第1-2步仅按需低剂量ICS-福莫特罗(轻度哮喘),第3-5步每日维持ICS-福莫特罗加按需缓解(MART)。
  • 替代轨(Track 2):所有步骤按需SABA,加规律ICS(第2步)或ICS-长效β2受体激动剂(第3-5步)。
  • 成人中重度哮喘第5步附加推荐长效毒蕈碱拮抗剂和阿奇霉素,重症哮喘附加生物制剂。
  • 6-11岁儿童第3-4步新增治疗选择。

临床怎么用

  • 成人及青少年哮喘不应单用SABA治疗,应优先考虑含ICS的方案。
  • 轻度哮喘首选按需低剂量ICS-福莫特罗作为缓解剂。
  • 中重度哮喘按GINA 2021分轨选择维持与缓解策略,第5步考虑附加治疗。
  • 所有年龄和严重度均应定期个体化评估、治疗可改变危险因素、自我管理教育、技能培训、适当调整药物和复查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting β2 -agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by ≥60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, "MART") in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting β2 -agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Respirology. 2022. PMID: 34668278. doi:10.1111/resp.14174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。